Abu Dhabi, UAE - Neopharma Inc., USA, a subsidiary of Abu Dhabi based UAE’ largest pharmaceutical manufacturer, Neopharma LLC, announced that in a 100% ownership transfer, it has acquired from Dr. Reddy’s Laboratories, Inc. a subsidiary of Dr. Reddy’s Laboratories Ltd. an antibiotic manufacturing facility and its related assets in Bristol, Tennessee (US).
The Bristol site has had a long history first with the British drug maker GlaxoSmithKline (GSK) and then with Dr. Reddy’s in manufacturing the brands Augmentin® and Amoxil®. The sale will enable the facility to continue providing oral penicillin-containing antibacterial products to patients in the United States. The 390,000-square-foot facility is dedicated to manufacturing and packaging oral-solid dose penicillin and has separate spaces for processing, packaging, development, printing, and warehousing.
Dr. B.R. Shetty, Founder & Chairman, Neopharma remarked “We are delighted to have this acquisition from Dr. Reddy’s Laboratories as the acquisition follows similar acquisitions made in Japan, Brazil and India and is a part of the global expansion drive for Neopharma, which is rapidly establishing itself as a global manufacturer of quality medications at affordable prices. The acquisition will strengthen the UAE’s presence in the global pharma space”.
Suresh Kumar Nandiraju, Chief Operating Officer of Neopharma, said, “This acquisition allows us to enter the United States penicillin-containing antibiotic market segment and marks our entry into the generic drug business in the US while providing opportunities to explore additional synergies with our other group companies. The acquisition will help us leverage our expertise in beta lactam manufacturing segment.”
Beta lactam is a class of broad-spectrum antibiotics, consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures.
Neopharma LLC, is one of the largest pharmaceutical companies in the MENA region. Neopharma is a vertically integrated business, providing economies of scale and with an extremely skilled team, Neopharma is able to deliver quality products in a timely manner at affordable prices in over 50 countries worldwide. Neopharma's global presence is supported by 5 manufacturing facilities spread across 3 continents delivering a wide range of branded and generic formulations, and active pharmaceutical ingredients (APIs). The therapeutic segments covered by our portfolio of over 100 high-quality molecules include anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, urology, dermatology, gynecology, respiratory, dental and nutritionals. Neopharma LLC also has 100% subsidiaries in Japan, India, Brazil, Russia, UK and USA
For further information, log on to: www.neopharma.com
About Neopharma Inc.:
Neopharma Inc. is a wholly owned, subsidiary of Abu Dhabi based, Neopharma LLC and was established in 2017 in Princeton, New Jersey. Core objectives of the company includes development, manufacturing and marketing of pharmaceuticals in USA and LATAM markets. The major therapeutic areas of focus are anti-infectives, cardiovascular, diabetology, oncology, respiratory & pain management.
About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. The major markets include – USA, India, Russia & CIS countries, and Europe.
For more information, log on to: www.drreddys.com
Neopharma LLC; Tel: +9712 550 1000
© Press Release 2018